GLP-1 Pill Fails to Slow Alzheimer’s Progression in Clinical Trial
Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral semaglutide failed to slow down Alzheimer's progression
Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral semaglutide failed to slow down Alzheimer's progression
What's Your Reaction?
SIN
ScienceX Information Network (SIN) | ScienceX Innovations
